Loading clinical trials...
Loading clinical trials...
A Phase I/II Double-Blind, Dose Ranging, Vehicle Controlled, Randomized, Parallel Groups, Safety, Tolerability and Efficacy Study of CHRONSEAL® (5-amino-acid Deleted Recombinant Human Hepatocyte Growth Factor (KP-dHGF)), in Subjects With Venous Leg Ulcers
Conditions
Interventions
CHRONSEAL
Locations
16
Norway
Medi3 Innlandet AS, Department Elverum
Elverum, Norway
Hudavdelingen Helse
Førde, Norway
Medi 3 Innlandet AS, Department Hamar
Hamar, Norway
Colosseumklinikken
Oslo, Norway
Vårdcentralen Alvesta
Alvesta, Sweden
Danderyds Sjukhus AB
Danderyd, Sweden
Start Date
November 1, 2008
Primary Completion Date
March 1, 2010
Completion Date
March 1, 2010
Last Updated
February 5, 2010
Lead Sponsor
Kringle Pharma Europe AB
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions